JOHN KIRKWOOD to DNA Mutational Analysis
This is a "connection" page, showing publications JOHN KIRKWOOD has written about DNA Mutational Analysis.
Connection Strength
0.109
-
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012 Jan 15; 18(2):555-67.
Score: 0.082
-
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res. 2016 Jan 15; 22(2):374-82.
Score: 0.027